SCCA Clinical Studies: Lung Cancer
|Closed||Non-small Cell Lung Cancer||Phase I/II||
The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.
- Men or women 18 years of age or older
- Must have Non-small Cell Lung Cancer with ALK+ mutation or other mutations or rearrangements potentially sensitive to crizotinib
- Measurable disease
- Must have been receiving or have received crizotinib
- Have adequate cardiac, bone marrow, liver and kidney function
- Must be willing and able to provide written informed consent and comply with the protocol and study procedures
- Prior anti-cancer treatment with any HSP90 inhibitor
- Have received chemotherapy, radiation therapy or other anticancer treatment other than crizotinib within 3 weeks prior to the first dose of study drug
- Prior malignancy other than adequately treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, low-grade cervical cancer, non-metastatic prostate cancer, or have been disease-free for at least 3 years
- Abnormal heart function
- Presence of a life-threatening illness, medical condition, organ system dysfunction, or other factors
- Hypersensitivity of AT13387 or other components of the drug product
- Treatment with an investigational drug within 3 weeks prior to the first dose of study drug
- Severe systemic diseases or active uncontrolled infections
- Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.